I’ve noticed something odd about how we talk about “safety” in inflammatory bowel disease: we often treat it as a binary switch—either a therapy causes dangerous infections or it doesn’t. But personally, I think the more realistic story is messier, because mild infections aren’t harmless in the lived experience of patients. They can wear down energy, disrupt routines, and quietly erode confidence in a treatment plan.
This gets particularly interesting with thiopurines like azathioprine and mercaptopurine, which have been used for decades. A population-based Swedish study followed people with IBD who were new to thiopurines and tracked infection rates over time. What makes the findings stand out, in my opinion, is not that mild infections happened—it’s the pattern: viral and upper respiratory infections appear to rise, while moderate-to-severe infections don’t show a clear increase. From my perspective, that distinction should change how clinicians counsel patients and how health systems evaluate “real-world tolerability.”
Mild infections, loud consequences
The study reported that overall infection incidence rose after starting thiopurines, from about 22.4 to 31.8 per 100 person-years. The headline number matters, but what I find especially interesting is what drove it: the risk increase leaned toward mild infections—particularly viral ones—and upper respiratory tract infections. Meanwhile, moderate-to-severe infections did not rise in a statistically meaningful way.
Personally, I think that’s where much of the public misunderstanding lives. People often hear “mild” and assume it’s clinically irrelevant, but mild does not mean trivial when it repeats. If you’re already dealing with chronic inflammation, intermittent symptoms, medication monitoring, and flare anxiety, then catching frequent respiratory viruses can feel like the treatment is working against you.
This raises a deeper question: what does “safe” really mean in everyday life? If a therapy doesn’t increase hospital-level infections but does increase day-to-day illness episodes, then quality of life becomes the battleground—not just ICU risk. What this really suggests is that safety evaluations should include patient function metrics, not only severe outcomes.
And here’s the broader trend this connects to: modern medicine loves measurable endpoints (hospitalizations, mortality, serious adverse events) because they’re clean for studies. But real patients experience side effects as interruptions—missed work, sleepless nights, social withdrawal, and a constant background worry. Personally, I think we’re overdue to treat those consequences as outcomes, not as collateral damage.
The viral pattern is the tell
One detail that immediately stands out is the shift in infection types after thiopurine initiation. Before treatment, bacterial infections were more common; afterward, viral infections took a larger share. Gastrointestinal infections decreased, while upper respiratory infections increased.
From my perspective, that viral-leaning pattern is a clue about mechanism and immune “tradeoffs.” Thiopurines suppress certain immune functions, and while that doesn’t necessarily translate into more severe infections, it may still reduce the margin of error your body needs to fight off common viruses. This is the kind of nuance that gets lost when we only ask, “Does the patient end up in the hospital?”
What many people don’t realize is that respiratory viruses are especially disruptive because they circulate constantly and are easy to catch in everyday settings. Even without severe disease, repeated exposure can produce a cycle: mild illness leads to fatigue and disrupted routines, which then affects adherence behaviors and the perceived stability of the disease.
This also implies a clinical opportunity. If viral and upper respiratory infections are the dominant issue, then prevention strategies—vaccination timing, early symptom management, possibly even occupational risk counseling—should be part of the thiopurine “package,” not an afterthought. In my opinion, the simplest supportive care might be underutilized because the community conversation has been too fixated on severe infections as the only meaningful warning sign.
Why the “no severe increase” point still demands nuance
The researchers concluded that thiopurine monotherapy remains relatively safe for maintaining remission, at least regarding moderate-to-severe infection risk. I agree with the overall reassurance—but I also think the framing can lull people into ignoring the cumulative burden.
A detail that I find especially interesting is how infection incidence increased while severe categories didn’t. That combination often means the immune impact is real but “contained,” producing more frequent mild events rather than more frequent emergencies. Personally, I think that should lead to a more sophisticated consent process: patients should understand not only whether serious infections rise, but also whether the rhythm of everyday illness changes.
If you take a step back and think about it, the public health implication is clear: even mild infections can increase healthcare utilization, antibiotic exposure (when uncertainty exists), missed appointments, and psychological stress. And stress, in turn, can worsen symptom perception and flare interpretation—especially in diseases like IBD where the mind-body interface is complicated.
So yes, the lack of a severe infection signal matters. But the presence of a mild infection signal matters more than we admit, because mild events are frequent enough to accumulate into real life costs.
Pre-existing infection risk and the story of vulnerability
The study also reported that having an infection before starting thiopurines increased the risk of subsequent infection. This is not surprising, but it’s still important, because it suggests patients enter treatment with differing levels of baseline vulnerability.
In my opinion, clinicians sometimes treat medication risk as if it were uniform across patients, but biology doesn’t work that way. If someone already had infections in the period leading up to therapy—whether due to disease activity, comorbidities, exposures, or immune status—then thiopurines may amplify a pre-existing pattern. What this really suggests is that “average risk” in studies can hide the fact that subgroups may experience more pronounced effects.
This raises a practical question: could tighter pre-treatment assessment improve the benefit-risk balance? For example, paying closer attention to vaccination status, recent infection history, and perhaps modifiable exposure risks could help clinicians identify who might need additional prevention support.
Personally, I think this is where editorial energy should go in the real world: not just “thiopurines are safe” versus “thiopurines are risky,” but “thiopurines are safe for most, with tailored vigilance for those who show patterns of vulnerability.”
The access problem behind the treatment choice
Another angle worth emphasizing is the context: the broader IBD treatment landscape has shifted toward biologics and small molecules, but their cost and availability limit widespread use. Thiopurines still play a role, particularly in settings where newer options aren’t accessible.
From my perspective, this matters because “safety” isn’t purely medical—it’s also logistical and economic. When access constraints push clinicians toward older therapies, infection-risk discussions can’t be abstract. Patients deserve honesty that includes the real-world tradeoff: you may avoid severe infections, but you might still face more mild viral illnesses.
What many people don’t realize is that health systems sometimes evaluate drug strategies in a way that undercounts day-to-day harms. If newer therapies are unavailable, then the question becomes: how do we optimize the older option responsibly? That optimization includes monitoring, prevention, and patient education about what to watch for.
So what should patients and clinicians do?
I don’t think the right response is fear. I do think the right response is specificity. Personally, I would want conversations that acknowledge mild infections as a meaningful downside, especially viral respiratory infections, even when severe events are not rising.
Here are a few practical implications I’d push for:
- Prevention should be proactive, especially around respiratory viruses, because the pattern points in that direction.
- Pre-treatment infection history should inform counseling, since baseline vulnerability seems to matter.
- “No severe increase” should not be presented as “no meaningful harm,” because cumulative mild illness can still affect function.
- Monitoring and early management plans should be discussed clearly, so patients aren’t left to interpret symptoms alone.
If you’re looking for the deeper takeaway, it’s this: medicine shouldn’t only ask whether a therapy is dangerous, but whether it’s livable.
The uncomfortable truth I wrestle with is that “safe” can become a marketing word when it’s stripped of context. This study reinforces that thiopurines can be a reasonable choice for maintaining remission—particularly where alternatives are limited. But it also asks us to respect the patient’s calendar, not just the patient’s blood counts: if mild viral infections become more common, then quality of life is part of the evidence we must take seriously. Personally, I think that’s the standard we should hold across all IBD therapies moving forward.
Would you like the article to skew more toward clinical implications (what doctors should do differently) or more toward patient-facing counseling language (how patients should interpret and manage the risk)?
